Clinical Report: Efficacy of Limus-Coated Balloons vs. Paclitaxel-Coated Balloons
Overview
This systematic review evaluates the efficacy of limus-coated balloons (Limus-DCB) compared to paclitaxel-coated balloons (PCB) in treating coronary artery disease. The findings indicate that there were no significant clinical differences observed between the two types of balloons.
Background
Coronary artery disease remains a leading cause of morbidity and mortality worldwide. The development of drug-coated balloons (DCBs) represents a significant advancement in percutaneous coronary intervention (PCI), offering a potential alternative to traditional stenting. Understanding the comparative effectiveness of different DCB types is crucial for optimizing treatment strategies and improving patient outcomes.
Data Highlights
Outcome
Limus-DCB
Paclitaxel-DCB
P-value
In-segment late lumen loss (LLL)
MD = 0.10
-
0.04
In-lesion minimal lumen diameter (MLD)
MD = -0.10
-
0.04
Key Findings
Limus-DCB showed marginally greater in-segment late lumen loss compared to PCB (MD = 0.10, P = 0.04).
Limus-DCB was associated with a marginally smaller in-lesion minimal lumen diameter (MD = -0.10, P = 0.04).
No significant differences were found in binary restenosis rate between Limus-DCB and PCB.
Target lesion failure (TLF) rates were similar between both groups.
Major adverse cardiovascular events (MACE) did not differ significantly between Limus-DCB and PCB.
Clinical Implications
Further high-quality research is needed to confirm these findings.
Conclusion
Further studies are warranted to validate these results.
